Relmada Therapeutics, Inc. (RLMD) — 10-Q Filings
All 10-Q filings from Relmada Therapeutics, Inc.. Browse 6 Quarterly Report reports with AI-powered summaries and risk analysis.
10-Q Filings (6)
-
Relmada Narrows Losses, Pivots Pipeline with $94M Capital Infusion
— Nov 13, 2025 Risk: medium
RELMADA THERAPEUTICS, INC. (RLMD) reported a significant net loss of $37,517,403 for the nine months ended September 30, 2025, compared to a net loss of $61,322 -
RELMADA Remains Pre-Revenue, NASDAQ Listed
— Aug 7, 2025 Risk: high
RELMADA THERAPEUTICS, INC. (RLMD) reported no revenue for the quarter ended June 30, 2025, consistent with its pre-commercial stage as a pharmaceutical preparat -
Relmada Therapeutics Files Q1 2025 10-Q
— May 12, 2025 Risk: low
Relmada Therapeutics, Inc. filed its quarterly report on Form 10-Q for the period ended March 31, 2025. The company, incorporated in Nevada, is involved in the -
Relmada Therapeutics Files Q3 2024 10-Q
— Nov 7, 2024 Risk: low
Relmada Therapeutics, Inc. filed its quarterly report for the period ending September 30, 2024. The company, previously known as Camp Nine, Inc., is incorporate -
Relmada Therapeutics Files Q2 2024 10-Q
— Aug 7, 2024 Risk: low
Relmada Therapeutics, Inc. filed its quarterly report for the period ended June 30, 2024. The company, formerly known as Camp Nine, Inc., is incorporated in Nev -
Relmada Therapeutics, Inc. Files Quarterly Report for Period Ended March 31, 2024
— May 8, 2024 Risk: low
RELMADA THERAPEUTICS, INC. (RLMD) filed a Quarterly Report (10-Q) with the SEC on May 8, 2024. Relmada Therapeutics, Inc. filed a Form 10-Q for the quarterly pe
Popular Companies
AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX